- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04533256
Effects of Renal Replacement Therapy With Hemoadsoption in Patients With Sepsis
September 3, 2021 updated by: Popescu Mihai, Institutul Clinic Fundeni
Hemoadsorption has been demonstrated to improve clinical and paraclinical results in critically ill patients with sepsis and septic shock.
The present study investigates the effects of three consecutive sessions of hemoadsorption, performed in accordance to the local protocol for treating patients with sepsis, on organ failure, severity scores and 30-days mortality.
Paraclinical results and severity scores were obtained before and after the three consecutive sessions.
Study Overview
Study Type
Observational
Enrollment (Actual)
30
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bucharest, Romania, 022328
- Fundeni Clinical Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with sepsis or septic shock who require hemoadsorption in accordance with local guidelines.
The decision of hemoadsorption is made by the attending physician prior to study inclusion.
Description
Inclusion Criteria:
- patients with sepsis or septic shock who require hemoadsorption in accordance with local guidelines
Exclusion Criteria:
- unsigned informed consent
- duration of therapy under 12 hours
- death before the three consecutive sessions
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
28-days mortality
Time Frame: 28 days after ICU admission
|
28-days mortality
|
28 days after ICU admission
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
severity score
Time Frame: 3 days
|
dynamics of SOFA score (Sequential Organ Failure Assessment) calculated as the mathematical difference in post-therapy SOFA score and pre-therapy SOFA score
|
3 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 10, 2016
Primary Completion (ACTUAL)
July 30, 2021
Study Completion (ACTUAL)
July 30, 2021
Study Registration Dates
First Submitted
August 26, 2020
First Submitted That Met QC Criteria
August 26, 2020
First Posted (ACTUAL)
August 31, 2020
Study Record Updates
Last Update Posted (ACTUAL)
September 13, 2021
Last Update Submitted That Met QC Criteria
September 3, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Cyto-Sepsis
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
-
Inverness Medical InnovationsCompletedSepsis | Systemic Inflammatory Response Syndrome | Severe Sepsis | Sepsis SyndromeUnited States
Clinical Trials on CytoSorb
-
CytoSorbents, IncRecruitingSepsis | Burns | Septic Shock | Trauma | Infectious Disease | Pancreatitis | Acute Respiratory Distress Syndrome | Liver Transplant; Complications | Drug Overdose | Acute Liver Failure | Cardiogenic Shock | Rhabdomyolysis | Acute on Chronic Liver Failure | Hemophagocytic Lymphohistiocytoses | Extracorporeal Life Support and other conditionsSpain, Italy, Germany, Portugal
-
Lund University HospitalCompletedLung Transplant Failure | Lung Transplant; ComplicationsSweden
-
Emma HanssonCytoSorbents, IncCompleted
-
Centre Hospitalier Universitaire VaudoisCompletedMyocardial Ischemia | Heart Valve DiseasesSwitzerland
-
RWTH Aachen UniversityCompletedPostoperative Complications | Inflammatory ResponseGermany
-
Emanuela KellerCytoSorbents Europe GmbHTerminated
-
Hannover Medical SchoolCytoSorbents, IncRecruitingCytokine Release Syndrome | CAR-TGermany, Switzerland
-
Medical University of ViennaRecruiting
-
Radboud University Medical CenterCytoSorbents Europe GmbHCompletedSepsis | Immune Deficiency | Hemoperfusion | Blood PurificationNetherlands
-
Universitätsklinikum Hamburg-EppendorfCompleted